Drug Safety

, Volume 30, Issue 3, pp 195–201 | Cite as

Psychiatric Adverse Reactions with Statins, Fibrates and Ezetimibe

Implications for the Use of Lipid-Lowering Agents
  • Michael TatleyEmail author
  • Ruth Savage
Leading Article


The HMG-CoA reductase inhibitors (‘statins’) have come into widespread use internationally. There has been a long history of their use in New Zealand and this use has increased in recent years. There has also been an increase in the number of reports to the New Zealand Centre for Adverse Reactions Monitoring (CARM) of suspected psychiatric adverse reactions associated with statins. The reactions mentioned in these reports include depression, memory loss, confusion and aggressive reactions. Convincing reports to CARM of recurrence of these reactions upon rechallenge add weight to recent studies reporting serious psychiatric disturbances in association with statin treatment. Aggressive reactions associated with statins are poorly documented in the literature. These observations emphasise the need to be vigilant in looking for these reactions as they can have a significant personal impact on a patient. The observation that other lipid-lowering agents have similar adverse effects supports the hypothesis that decreased brain cell membrane cholesterol may be important in the aetiology of these psychiatric reactions.


Statin Simvastatin Atorvastatin Ezetimibe Fluvastatin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The Ministry of Health, New Zealand, funds, under contract, the New Zealand Pharmacovigilance Centre, a unit within the Department of Preventive and Social Medicine at the University of Otago, to provide national adverse drug reaction monitoring services. No additional sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997 Jul 23-30; 278(4): 313–21PubMedCrossRefGoogle Scholar
  2. 2.
    Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 1998 Jan 15; 128(2): 89–95PubMedGoogle Scholar
  3. 3.
    Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001 Jun; 21(6): 767–9PubMedCrossRefGoogle Scholar
  4. 4.
    Scott HD, Laake K. Statins for the reduction of risk of Alzheimer’s disease. Cochrane Database Syst Rev 2001 (3): CD003160PubMedGoogle Scholar
  5. 5.
    Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004 Apr; 97(4): 229–35PubMedCrossRefGoogle Scholar
  6. 6.
    Simons J. The $10 billion pill. Fortune. 2003 Jan 20; 147(1): 58–62PubMedGoogle Scholar
  7. 7.
    Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs 2001; 61(2): 197–206PubMedCrossRefGoogle Scholar
  8. 8.
    Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ 2001 Aug 18; 323(7309): 359CrossRefGoogle Scholar
  9. 9.
    Savage R, Tatley M. Myopathy with statins: check CK levels and interactions. Prescriber Update 2004 May; 25(1): 4–5Google Scholar
  10. 10.
    Golomb BA, Criqui MH, White H, et al. Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. Arch Intern Med 2004 Jan 26; 164(2): 153–62PubMedCrossRefGoogle Scholar
  11. 11.
    Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002 May 14; 58(9): 1333–7PubMedCrossRefGoogle Scholar
  12. 12.
    Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003 Jul; 23(7): 871–80PubMedCrossRefGoogle Scholar
  13. 13.
    King DS, Wilburn AJ, Wofford MR, et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003 Dec; 23(12): 1663–7PubMedCrossRefGoogle Scholar
  14. 14.
    Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemia adults. Am J Med 2004 Dec 1; 117(11): 823–9PubMedCrossRefGoogle Scholar
  15. 15.
    Manfredini R, Caracciolo S, Salmi R, et al. The association of low serum cholesterol with depression and suicidal behaviours: new hypotheses for the missing link. J Int Med Res 2000 Nov-Dec; 28(6): 247–57PubMedGoogle Scholar
  16. 16.
    Vevera J, Fisar Z, Kvasnicka T, et al. Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res 2005 Feb 28; 133(2-3): 197–203PubMedCrossRefGoogle Scholar
  17. 17.
    Golomb BA, Stattin H, Mednick S. Low cholesterol and violent crime. J Psychiatr Res 2000 Jul-Oct; 34(4-5): 301–9PubMedCrossRefGoogle Scholar
  18. 18.
    Golomb BA. Cholesterol and violence: is there a connection? Ann Intern Med 1998 Mar 15; 128(6): 478–87PubMedGoogle Scholar
  19. 19.
    Saheki A, Terasaki T, Tamai I, et al. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994 Feb; 11(2): 305–11PubMedCrossRefGoogle Scholar
  20. 20.
    Engelberg H. Low serum cholesterol and suicide. Lancet 1992 Mar 21; 339(8795): 727–9PubMedCrossRefGoogle Scholar
  21. 21.
    Wardle J, Rogers P, Judd P, et al. Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function. Am J Med 2000 May; 108(7): 547–53PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.New Zealand Pharmacovigilance Centre, Department of Preventative and Social MedicineUniversity of OtagoDunedinNew Zealand

Personalised recommendations